The FNIH Biomarkers Consortium’s Neursocience Steering Committee convened a meeting within its Clinical Endpoints for Anhedonia working group at the FASEB Campus from Feb. 18-19, 2016. The meeting gathered scientific researchers from academia, governmental institutions, regulatory agencies and pharmaceutical companies to facilitate communication and accelerate the process of aligning objective functional circuit-based measures of “reward” or “positive valence” in Research Domain Criteria (RDoC) that could be coupled with clinical measures to better define and operationalize the potential drug targets of “anhedonia,” “amotivation” and “apathy” across a broad range of Central Nervous System and addictive disorders.
The meeting objective was to develop a list of possible assessments to use in future drug development trials. Attendees were especially interested in identifying measures that reliably produce a signal in individuals that draws strong conclusions about pharmacological target engagement and that could be used across indications and patient groups. The discussions focused on fMRI, EEG, ERP and stand-alone behavioral measures, especially those with good translational utility in animal and preclinical studies.
For additional information, please contact Joseph P. Menetski, Ph.D., Associate Vice President of Research Partnerships at [email protected] or (301) 594-6596.